Literature DB >> 9028340

The primate erythrocyte complement receptor (CR1) as a privileged site: binding of immunoglobulin G to erythrocyte CR1 does not target erythrocytes for phagocytosis.

M L Reinagel1, M Gezen, P J Ferguson, S Kuhn, E N Martin, R P Taylor.   

Abstract

The primate erythrocyte (E) complement receptor, CR1, is a transmembrane glycoprotein located in clusters on the surface of E. In vivo studies have demonstrated that during processing and clearance of complement-opsonized immune complexes, large amounts of immunoglobulin G (IgG) can be bound to primate E via CR1 with no E loss or lysis. However, when comparable amounts of IgG are bound to other sites on E, in many cases the E are cleared from the circulation by the mononuclear phagocytic system. Therefore, due to its role in immune complex processing, CR1 may represent a privileged site on the primate E. To delineate further this property of E CR1, we performed in vitro phagocytosis assays in the absence of complement and examined the ingestion of E, opsonized at various sites with IgG, by peripheral blood monocytes. When either human or rhesus monkey E were opsonized at sites other than CR1, with between 1,000 and 15,000 IgG per E, substantial phagocytosis of E was evident. However, when comparable amounts of IgG were bound exclusively via CR1, little, if any, phagocytosis was observed. The key to the low phagocytic level of E opsonized via CR1 may be related to the requirements of a "zipper mechanism" for phagocytosis first annunciated by Griffin et al. Based on their findings, we suggest that due to the presence of preexisting clusters of CR1 on the E membrane, large amounts of IgG can be bound to E under conditions that preclude circumferential engagement (and phagocytosis) of the entire E by Fc receptors on the monocyte.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028340

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

Review 1.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

2.  Use of mosquito preventive measures is associated with increased RBC CR1 levels in a malaria holoendemic area of western Kenya.

Authors:  Christine King; Ping Du; Walter Otieno; José A Stoute
Journal:  Am J Trop Med Hyg       Date:  2014-11-10       Impact factor: 2.345

Review 3.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 4.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

5.  Reduced immune complex binding capacity and increased complement susceptibility of red cells from children with severe malaria-associated anemia.

Authors:  Boaz O Owuor; Collins O Odhiambo; Walter O Otieno; Christine Adhiambo; Dominic W Makawiti; José A Stoute
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

6.  Loss of complement regulatory proteins on red blood cells in mild malarial anaemia and in Plasmodium falciparum induced blood-stage infection.

Authors:  Damian A Oyong; Jessica R Loughland; Arya SheelaNair; Dean Andrew; Fabian D L Rivera; Kim A Piera; Timothy William; Matthew J Grigg; Bridget E Barber; Ashraful Haque; Christian R Engwerda; James S McCarthy; Nicholas M Anstey; Michelle J Boyle
Journal:  Malar J       Date:  2019-09-18       Impact factor: 2.979

7.  Possible influence of resistance to malaria in clinical presentation of rheumatoid arthritis: biological significance of natural selection.

Authors:  Fabio Bonilla-Abadía; Gabriel J Tobón; Carlos A Cañas
Journal:  Arthritis       Date:  2012-11-14

8.  Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: implications for the development of severe anemia.

Authors:  Collins O Odhiambo; Walter Otieno; Christine Adhiambo; Michael M Odera; José A Stoute
Journal:  BMC Med       Date:  2008-08-21       Impact factor: 8.775

9.  Complement consumption in children with Plasmodium falciparum malaria.

Authors:  Nancy K Nyakoe; Ronald P Taylor; Joseph N Makumi; John N Waitumbi
Journal:  Malar J       Date:  2009-01-09       Impact factor: 2.979

Review 10.  Therapeutic applications of monoclonal antibodies.

Authors:  Mitchell Berger; Vidya Shankar; Abbas Vafai
Journal:  Am J Med Sci       Date:  2002-07       Impact factor: 2.378

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.